A study [81] has proposed that PSMA PET/CT can be used as an imaging method for staging and restaging of RCC to improve the staging sensitivity, which can directly lead to the change of treatment in some cases, particularly, in the application of metastatic ccRCC. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.